Gül FİKİRLİ, İlker ÖZEÇ, Reyhan EĞİLMEZ, Fahrettin GÖZE

Oral Lökoplaki Ve Oral Skuamoz Hücreli Karsinomada Ghrelin Seviyelerinin Değerlendirilmesi: İmmünhistokimyasal Çalışma

AMAÇ: Biobelirteçler normal dokuda, prekanseröz lezyonlarda ve kanserli dokuda farklı miktarlarda bulunabilen proteinler veya genlerdir, biobelirteçlerin değerlendirilmesi daha etkin bir şekilde malign transformasyon öngörüsü yapılmasını sağlayabilir. Bu çalışmanın amacı normal oral epitel, oral lökoplaki ve oral skuamoz hücreli karsinomada (OSHK) ghrelin seviyelerinin araştırılarak karşılaştırılmasıdır. YÖNTEM: Patoloji bölümü arşivinden elde edilen toplam 55 adet daha önce tanısı konulmuş normal oral mukoza (n = 15), oral lökoplaki (n = 18) ve OSHK (n = 22) bloklarından deparafinize edilerek elde edilen preparatlar özel antikorlar kullanılarak immünhistokimyasal olarak boyanmış ve ghrelin seviyeleri değerlendirilmiştir. İmmünhistokimyasal boyamada ghrelin mevcudiyeti mikroskop altında 100 hücre değerlendirilerek sayısallaştırılmıştır. Ghrelin pozitif hücrelerde kahverengi sitoplazmik boyama görülmüştür. BULGULAR: Normal oral mukozada hücrelerinin % 64'ünde, oral lökoplaki hücrelerinin % 66'sında ghrelin pozitif boyama görülürken, OSHK'da bu boyama yalnızca hücrelerin % 8'inde olmuştur. Diğer gruplar ile karşılaştırıldığı zaman OSHK grubunda ghrelin pozitif boyalı hücre miktarının istatistiksel olarak anlamlı şekilde az olduğu görülmüştür (P < 0.05). SONUÇ: Normal oral mukoza ve oral lökoplaki ile karşılaştırıldığı zaman OSHK grubunda ghrelin seviyesinin daha az olduğu tespit edilmiştir. Oral lökoplaki ve normal oral mukoza gruplarının ghrelinin seviyelerinin benzer olduğu belirlenmiştir. Oral karsinogenezis ile birlikte oluşan ghrelin seviyesinde ki değişikliklerin artmış malign potansiyelin belirlenmesinde bir biobelirteç olabileceği düşünülmektedir.

The Evaluation Of Ghrelin Expression In Oral Leukoplakia And Oral Squamous Cell Carcinoma: An Immunohistochemical Study

INTRODUCTION: Biomarkers are proteins or genes that can be differentially expressed in cancer, premalign, and normal tissue and the use of biomarkers may help to improve prediction of cancer transformation. The aim of this study was to investigate whether ghrelin is differently expressed in normal oral epithelium, oral leukoplakia, and oral squamous cell carcinoma (OSCC). METHODS: Preparations of deparaffinized blocks obtained from the pathology archives of 55 previously diagnosed cases of normal oral mucosa (n = 15), oral leukoplakia (n = 18), and OSCC (n = 22) were stained immunohistochemically with specific antibodies to evaluate ghrelin expression. The ghrelin expression on immunohistochemical staining was quantified visually by counting 100 cells under a microscopic. Ghrelin-positive cells showed brown cytoplasmic staining. RESULTS: Ghrelin was expressed in 64% of normal oral mucosa, 66% of oral leukoplakia, but in only 8% of OSCC. Compared with the other two groups, the mean ghrelin expression decreased significantly (P < 0.05) in the OSCC group. CONCLUSION: Ghrelin expression is decreased in OSCC compared with normal oral mucosa and oral leukoplakia. The ghrelin levels were similar in oral leukoplakia and normal oral mucosa. Ghrelin expression changes with oral carcinogenesis may be a biomarker for determining increased malignant potential.

PDF

___

1. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2010; 45: 309-316.
2. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature. and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007; 36: 575-580.
3. Woo SB, Grammer RL, Lerman MA. Keratosis of unknown significance and leukoplakia: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol 2014; 118: 713-724.
4. Fleskens S, Slootweg P. Grading systems in head and neck dysplasia: their prognostic value, weaknesses and utility. Head Neck Oncol 2009; 1: 1-8.
5. Rhodus NL, Kerr AR, Patel K. Oral cancer: leukoplakia, premalignancy, and squamous cell carcinoma. Dent Clin North Am 2014; 58: 315-340.
6. Scully C. Challenges in predicting which oral mucosal potentially malignant disease will progress to neoplasia. Oral Dis 20; 1420: 1-5.
7. Warnakulasuriya S, Reibel J, Bouquot J, et al. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 2008; 37: 127-133.
8. Brouns E, Baart J, Karagozoglu K, et al. Malignant transformation of oral leukoplakia in a well-defined cohort of 144 patients. Oral Dis 2014; 20: 19-24.
9. Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in thgastrointestinal tracts of rats and humans. Endocrinology 2000; 141: 4255-4261.
10. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
11. Lee HM, Wang G, Englander EW, et al. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 2002; 143: 185-190.
12.Jeffery PL, Herington AC, Chopin LK. The potential autocrine/ paracrine roles of ghrelin and its receptor in hormone- dependent cancer. Cytokine Growth Factor Rev 2005; 14: 113-122.
13. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495-522.
14. Chopin LK, Seim I, Walpole CM, et al. The ghrelin axis--does it have an appetite for cancer progression? Endocr Rev 2012; 33: 849-891.
15. Kraus D, Reckenbeil J, Wenghoefer M, et al. Ghrelin promotes oral tumor cell proliferation by modifying GLUT1 expression. Cell Mol Life Sci 2016; 73: 1287-1299.
16. Omoto I, Matsumoto M, Uchikado Y, et al. Immunohistochemical evidence of association between ghrelin expression and tumor growth in esophageal carcinoma. Anticancer Res 2014; 34: 2727-2733.
17. Karaoglu A, Aydin S, Dagli AF, et al. Expression of obestatin and ghrelin in papillary thyroid carcinoma. Mol Cell Biochem 2009; 323: 113-118.
18. Lu C, McFarland MS, Nesbitt RL, et al. Ghrelin receptor as a novel imaging target for prostatic neoplasms. Prostate 2012; 72: 825-833.
19. Alnema MM, Aydin S, Ozkan Y, et al. Ghrelin and obestatin expression in oral squamous cell carcinoma: an immunohistochemical and biochemical study. Mol Cell Biochem 2010; 339: 173-179.
20. Gröschl M, Topf HG, Bohlender J, et al. Identification of ghrelin in human saliva: production by the salivary glands and potential role in proliferation of oral keratinocytes. Clin Chem 2005; 51: 997-1006.
21. Liu B, Han X, Feng W, et al. Altered distribution of Ghrelin protein in mice molar development. Arch Oral Biol 2016; 65: 82-86.
22. Ohta K, Laborde NJ, Kajiya M, et al. Expression and possible immune-regulatory function of ghrelin in oral epithelium. J Dent Res 2011; 90: 1286-1292.
23. Nankivell P, Mehanna H. Oral dysplasia: biomarkers, treatment, and follow-up. Curr Oncol Rep 2011; 13: 145-152.
24. Ram H, Sarkar J, Kumar H, et al. Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg 2011; 10: 132-137. 25. Dalley AJ, Abdul Majeed AA, Pitty LP. LGR5 expression in oral epithelial dysplasia and oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2011; 119: 436-440.
26. Kamperos G, Nikitakis N, Sfakianou A, et al. Expression of NF-?B and IL-6 in oral precancerous and cancerous lesions: An immunohistochemical study. Med Oral Patol Oral Cir Bucal 2016; 21: 6-13.
27. Nasser W, Flechtenmacher C, Holzinger D, et al. Aberrant expression of p53, p16INK4a and Ki-67 as basic biomarker for malignant progression of oral leukoplakias. J Oral Pathol Med 2011; 40: 629-635.
28. Sawant SS, Vaidya MM, Chaukar DA, et al. Clinical significance of aberrant vimentin expression in oral premalignant lesions and carcinomas. Oral Dis 2014; 20: 453-465.
29. Lodi G, Porter S. Management of potentially malignant disorders: evidence and critique. J Oral Pathol Med 2008; 37: 63-69.
30. Aydin S, Ozercan IH, Dagli F, et al. Ghrelin immunohistochemistry of gastric adenocarcinoma and mucoepidermoid carcinoma of salivary gland. Biotech Histochem 2005; 80: 163-168.
31. Dagli AF, Aydin S, Karaoglu A, et al. Ghrelin expression in normal kidney tissue and renal carcinomas. Pathol Res Pract 2009; 205: 165-173.
32. Dagli AF, Aydin S, Kocdor H, et al. Ghrelin expression of endometrium hyperplasia and endometrioid carcinoma. Gynecol Endocrinol 2011; 27: 199-204.
33. Gronberg M, Fjallskog ML, Jirstrom K, et al. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer. Acta Oncol 2012; 51: 386-393.
34. Nurkalem C, Celik H, Dagli F, et al.Ghrelin and obestatin expression in serous ovarian tumours. Gynecol Endocrinol 2012; 28: 941-944.
35. Waseem T, Javaid-Ur-Rehman, Ahmad F, et al. Role of ghrelin axis in colorectal cancer: a novel association. Peptides 2008; 29: 1369-1376.
36. Özçaka Ö, Epstein JB, Güneri P. Inflammation in the assessment of salivary cytokines in oral squamous cell carcinoma diagnosis. Oral Oncol 2017;71: 96-98.